Clinuvel Pharmaceuticals Ltd.
Clinuvel Pharmaceuticals Ltd.
- Market cap
- $245.11M
- P/E ratio
- 10.72
Your view on CUVL
Overview
What the company does, where it operates, and who runs it.
About Clinuvel Pharmaceuticals Ltd.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Philippe Jacques Wolgen
- Headquarters
- 535 Bourke Street, Melbourne, VIC, AU
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders.
In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Clinuvel Pharmaceuticals Ltd.. Starting points for Clinuvel Pharmaceuticals Ltd.: P/E 10.7, EPS $0.68, beta 0.57 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. paid $0.04 per share over the last year — a 0.7% yield at the current $4.86 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Clinuvel Pharmaceuticals Ltd.. Trailing twelve-month EPS for Clinuvel Pharmaceuticals Ltd. stands at $0.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| QMDTQuick-Med Technologies, Inc. | Healthcare | OTC | $11,204 | ||
| RADLYRaia Drogasil S.A. | Healthcare | OTC | $8.8B | ||
| RBIIRising BioSciences, Inc. | Healthcare | OTC | $4,991 | ||
| RCDTFRecordati Industria Chimica e Farmaceutica S.p.A. | Healthcare | OTC | $11.6B | ||
| RGEDFGedeon Richter PLC | Healthcare | OTC | $5.7B | ||
| RLLVFRelevium Technologies Inc. | Healthcare | OTC | $2.0M | ||
| RMRKRimrock Gold Corp. | Healthcare | OTC | $234,228 | ||
| ROTHPharmaRoth Labs, Inc. | Healthcare | OTC | $35,118 | ||
| RPGLFRegent Pacific Group Limited | Healthcare | OTC | $36.5M | ||
| RPRXRoyalty Pharma plc | Healthcare | NASDAQ | $30.6B | ||
| RSCIRedwood Scientific Technologies, Inc. | Healthcare | OTC | $1,872 | ||
| RTEZRest Ez Inc. | Healthcare | OTC | $1.9B | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Clinuvel Pharmaceuticals Ltd.. Coverage tracks Clinuvel Pharmaceuticals Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Clinuvel Pharmaceuticals Ltd.